Strategic Partnerships Odylia already collaborates with Save Sight Now and Medibanx, and has secured a grant from Critical Path Institute, signaling established pathways for co-development, patient recruitment, and funded research engagements. This ecosystem presents ready-to-engage opportunities for CRO partnerships, grant support, and data-sharing arrangements to accelerate programs.

Gene Therapy Focus The company is pursuing gene-agnostic therapies with a focus on Usher syndrome Type 1C, creating opportunities to provide specialized preclinical services, assay development, and platform collaborations to accelerate rare-disease gene therapy programs.

Mission-Driven Advantage Odylia's nonprofit model prioritizes patient access over commercial scale, which can appeal to foundations, philanthropic sponsors, and CSR initiatives. This opens doors for sponsored research, milestone-based partnerships, and cost-sharing collaborations with industry partners.

Leadership Network Leadership under Ashley Winslow, Ph.D., as CEO and CSO, lends strong scientific credibility and continuity for academic partnerships, grant applications, and visibility within the rare-disease research community.

Regional & Data Assets Based in Atlanta with connections to patient groups and research consortia, Odylia can leverage regional academic centers and patient registries (e.g., via Medibanx) for trial sites, recruitment, and real-world data collaborations.